Reasons for study exclusion during stage 2 screening wereabsence of FEC-D chemotherapy use (n = 32), lack of individual results withinthe breast cancer population (n = 8), systematic review/review article (n = 5),absence of FN data (n = 3), metastatic breast cancer (n = 3), economic analysis(n = 2), multiple chemotherapy regimens used (n = 2), secondary FN prophylaxis(n = 2), no G-CSF or antibiotics interventions (n = 1), duplicate publication (n= 1), and non–breast cancer study (n = 1). This evidence concerns the gene CSF3 and breast cancer.